CLDX
Celldex Therapeutics, Inc. NASDAQ Listed May 15, 1986$33.31
After hrs
$33.97
+0.00%
Mkt Cap $2.2B
52w Low $18.00
86.1% of range
52w High $35.79
50d MA $31.70
200d MA $26.73
P/E (TTM)
-8.3x
EV/EBITDA
-7.0x
P/B
4.1x
Debt/Equity
0.0x
ROE
-49.1%
P/FCF
-8.5x
RSI (14)
—
ATR (14)
—
Beta
1.20
50d MA
$31.70
200d MA
$26.73
Avg Volume
1.0M
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Perryville III Building · Hampton, NJ 08827 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -1.15 | -1.18 | -2.9% | 33.32 | +4.9% | +2.0% | — | — | — | — | — |
| Feb 25, 2026 | AMC | -1.00 | -1.22 | -22.0% | 30.82 | -2.5% | -0.6% | -2.4% | -2.7% | -6.1% | -4.2% | — |
| Nov 10, 2025 | AMC | -0.88 | -1.01 | -14.8% | 22.67 | -1.8% | +7.5% | +7.0% | +4.6% | +12.7% | +14.7% | — |
| Aug 7, 2025 | AMC | -0.86 | -0.85 | +1.2% | 21.21 | -4.4% | -2.6% | -5.7% | +12.2% | +17.8% | +17.6% | — |
| May 8, 2025 | AMC | -0.75 | -0.81 | -8.0% | 19.52 | -6.8% | -6.1% | +3.4% | +0.5% | -3.0% | +3.0% | — |
| Feb 27, 2025 | AMC | -0.73 | -0.71 | +2.7% | 20.31 | -2.0% | +1.3% | -4.7% | -1.5% | +3.9% | +5.0% | — |
| Nov 6, 2024 | AMC | -0.69 | -0.64 | +7.2% | 27.63 | +1.3% | -4.2% | -5.1% | -5.1% | -2.2% | -2.9% | — |
| Aug 8, 2024 | AMC | -0.59 | -0.54 | +8.5% | 32.71 | +0.4% | +0.6% | +2.3% | +1.7% | -1.2% | +1.2% | — |
| May 6, 2024 | AMC | -0.67 | -0.56 | +16.4% | 41.65 | -1.4% | +1.3% | -1.1% | -1.4% | -4.2% | -3.7% | — |
| Feb 26, 2024 | AMC | -0.76 | -0.57 | +25.0% | 48.23 | +1.9% | +5.8% | +6.5% | -0.4% | +7.6% | +5.1% | — |
| Nov 2, 2023 | AMC | -0.67 | -0.81 | -20.9% | 24.01 | +5.8% | +8.2% | +22.2% | +20.9% | +10.4% | +7.4% | — |
| Aug 8, 2023 | AMC | -0.65 | -0.65 | +0.0% | 32.41 | -13.3% | -5.8% | -5.7% | -6.7% | -4.1% | -3.0% | — |
| May 4, 2023 | AMC | -0.63 | -0.62 | +1.6% | 31.49 | +0.1% | +5.7% | +5.9% | +5.2% | +6.6% | +5.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Barclays | Upgrade | Underweight → Overweight | — | $34.55 | $35.79 | +3.6% | -0.5% | -0.9% | -1.0% | -2.9% | -3.6% |
| Mar 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $30.09 | $29.94 | -0.5% | -0.3% | -3.8% | -1.8% | -2.4% | -2.2% |
| Feb 26 | Stifel | Maintains | Buy → Buy | — | $30.82 | $30.05 | -2.5% | -0.6% | -2.4% | -2.7% | -6.1% | -4.2% |
| Dec 17 | Barclays | Maintains | Underweight → Underweight | — | $26.68 | $26.59 | -0.3% | -3.4% | -5.2% | -4.0% | +2.2% | -0.4% |
| Nov 11 | Barclays | Maintains | Underweight → Underweight | — | $22.67 | $22.26 | -1.8% | +7.5% | +7.0% | +4.6% | +12.7% | +14.7% |
| Sep 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $24.58 | $24.32 | -1.1% | -0.5% | +5.5% | +0.1% | +1.1% | -1.4% |
| Aug 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $24.02 | $21.96 | -8.6% | -13.0% | -8.3% | -6.5% | -8.7% | -9.5% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.02 | $21.96 | -8.6% | -13.0% | -8.3% | -6.5% | -8.7% | -9.5% |
| Aug 20 | Citigroup | Maintains | Buy → Buy | — | $24.02 | $21.96 | -8.6% | -13.0% | -8.3% | -6.5% | -8.7% | -9.5% |
| Aug 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $24.02 | $21.96 | -8.6% | -13.0% | -8.3% | -6.5% | -8.7% | -9.5% |
| Jun 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.26 | $21.43 | +0.8% | -4.3% | -5.6% | -2.1% | -3.6% | -4.1% |
| Jun 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.35 | $20.21 | -0.7% | +4.5% | -0.0% | -1.4% | +2.3% | +0.7% |
| May 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $19.52 | $18.20 | -6.8% | -6.1% | +3.4% | +0.5% | -3.0% | +3.0% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.52 | $18.20 | -6.8% | -6.1% | +3.4% | +0.5% | -3.0% | +3.0% |
| May 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.52 | $18.20 | -6.8% | -6.1% | +3.4% | +0.5% | -3.0% | +3.0% |
| May 9 | UBS | Maintains | Buy → Buy | — | $19.52 | $18.20 | -6.8% | -6.1% | +3.4% | +0.5% | -3.0% | +3.0% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.29 | $20.00 | -1.4% | -9.3% | -6.8% | -3.8% | -9.7% | -0.5% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.57 | $21.27 | +3.4% | -5.9% | -2.8% | +2.6% | +3.7% | +0.5% |
| Mar 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $20.57 | $21.27 | +3.4% | -5.9% | -2.8% | +2.6% | +3.7% | +0.5% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.31 | $19.90 | -2.0% | +1.3% | -4.7% | -1.5% | +3.9% | +5.0% |
| Jan 2 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $25.27 | $25.54 | +1.1% | +2.1% | +6.1% | +5.2% | +9.2% | +5.0% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.38 | $25.18 | -0.8% | -0.9% | -2.4% | -1.0% | +1.1% | +0.0% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.82 | $24.81 | -0.0% | +2.3% | +1.3% | -0.2% | +1.2% | +3.3% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.98 | $25.00 | +0.1% | +5.7% | +5.0% | +8.2% | +12.7% | +7.1% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.63 | $28.00 | +1.3% | -4.2% | -5.1% | -5.1% | -2.2% | -2.9% |
| Oct 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.95 | $27.29 | +1.3% | +3.8% | -0.3% | -2.3% | -3.3% | -4.7% |
| Aug 12 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $32.92 | $33.13 | +0.6% | +1.6% | +1.1% | -1.8% | +0.5% | +3.8% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.92 | $33.13 | +0.6% | +1.6% | +1.1% | -1.8% | +0.5% | +3.8% |
| Jul 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.99 | $38.30 | -8.8% | -8.5% | -9.2% | -10.6% | -17.2% | -22.1% |
| Jul 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.99 | $38.30 | -8.8% | -8.5% | -9.2% | -10.6% | -17.2% | -22.1% |
| Jul 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.55 | $40.10 | +1.4% | +1.1% | -1.9% | -5.0% | -7.1% | -8.1% |
| Jun 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $34.91 | $35.92 | +2.9% | -0.7% | +2.2% | +1.0% | +3.6% | +3.7% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.30 | $34.20 | +2.7% | +0.5% | -1.6% | -0.9% | +5.4% | +5.9% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.47 | $40.97 | +3.8% | +1.8% | +1.2% | -3.2% | -4.4% | -4.6% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.65 | $41.07 | -1.4% | +1.3% | -1.1% | -1.4% | -4.2% | -3.7% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.60 | $39.01 | +1.1% | +2.7% | -0.2% | -1.6% | +0.6% | -2.2% |
| Mar 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.01 | $41.63 | +1.5% | +2.4% | +1.0% | +0.1% | +1.9% | +2.3% |
| Feb 27 | Guggenheim | Maintains | Buy → Buy | — | $48.23 | $49.13 | +1.9% | +5.8% | +6.5% | -0.4% | +7.6% | +5.1% |
| Nov 10 | Wells Fargo | Upgrade | Underweight → Equal Weight | — | $25.78 | $26.91 | +4.4% | +4.5% | +4.6% | +8.2% | +10.7% | +7.8% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.98 | $32.98 | +26.9% | +13.0% | +11.7% | +2.0% | -0.8% | +3.7% |
| Nov 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $24.01 | $25.40 | +5.8% | +8.2% | +22.2% | +20.9% | +10.4% | +7.4% |
| Oct 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $28.01 | $27.81 | -0.7% | -5.4% | -6.7% | -4.4% | -12.1% | -14.3% |
| Sep 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $26.51 | $26.84 | +1.2% | +3.1% | +5.6% | +3.8% | +3.2% | -0.9% |
| Aug 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.43 | $31.44 | +0.0% | -4.1% | -5.1% | -3.9% | -2.7% | -7.8% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.52 | $30.65 | +0.4% | +0.1% | -1.0% | +1.8% | +3.0% | -1.2% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.41 | $28.11 | -13.3% | -5.8% | -5.7% | -6.7% | -4.1% | -3.0% |
| Jun 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.80 | $35.65 | +2.4% | +6.6% | +10.0% | +8.0% | +5.9% | +2.5% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.18 | $31.29 | +0.4% | +2.0% | +3.0% | +6.4% | +9.1% | +12.2% |
| May 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.49 | $31.52 | +0.1% | +5.7% | +5.9% | +5.2% | +6.6% | +5.0% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.49 | $31.52 | +0.1% | +5.7% | +5.9% | +5.2% | +6.6% | +5.0% |
No insider trades available.
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Underwriting / Securities
CLDX entered into an underwriting agreement with Leerink Partners, likely signaling an upcoming secondary offering that could dilute existing shareholders but provide needed capital for operations or acquisitions.
Apr 2
8-K
Celldex Therapeutics, Inc -- 8-K Filing
Celldex Therapeutics' barzolvolimab advanced efficacy data and ahead-of-schedule Phase 3 enrollment completion in chronic spontaneous urticaria suggest positive momentum that could support future regulatory approvals and revenue growth.
Feb 25
Data updated apr 25, 2026 1:37am
· Source: massive.com